Related Experiment Video
Updated: Jul 4, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
High Mobility Group Box 1 Gene Polymorphism and Serum High Mobility Group Box 1, Interleukin 1 Beta, and Alpha-Klotho
Maha Houssen1, Rasha El-Mahdy2, Nouran E Samra2
1Biochemistry Department, Faculty of Pharmacy, Damanhour University, Damnhour, Egypt.
Insights
Serum levels of HMGB1, IL1β, and α-klotho are elevated in critically ill COVID-19 patients. These biomarkers, along with HMGB1 rs1045411 polymorphism, may indicate disease severity and offer therapeutic targets.
Area of Science:
- Biochemistry
- Immunology
- Genetics
Background:
- COVID-19 severity varies, necessitating biomarkers for prognosis.
- HMGB1, IL1β, and α-klotho are implicated in inflammatory and cellular processes.
Purpose of the Study:
- Evaluate serum HMGB1, IL1β, and α-klotho in COVID-19 patients across severity spectrums.
- Correlate these markers with clinicopathological parameters.
- Assess HMGB1 rs1045411 polymorphism and its association with COVID-19 severity.
Main Methods:
- Serum samples from 120 COVID-19 patients and 80 controls were analyzed.
- HMGB1, IL1β, and α-klotho levels measured using ELISA.
- HMGB1 rs1045411 polymorphism genotyped via RT-PCR.
Main Results:
- Significantly higher serum HMGB1, IL1β, and α-klotho in critically ill COVID-19 patients.
- HMGB1 rs1045411 polymorphism showed decreased T/T genotype frequency in patients versus controls.
- ROC analysis indicated moderate diagnostic utility for these serum markers.
Conclusions:
- Serum HMGB1, IL1β, and α-klotho may serve as indicators of COVID-19 severity.
- These biomarkers represent potential therapeutic targets for COVID-19 management.
Aim:
To evaluate the serum levels of HMGB1, IL1β, and α-klotho in COVID-19 patients with different disease severity, investigate their association with clinicopathological parameters, and to assess HMGB1 rs1045411 polymorphism and its relation with clinical severity.
Methods:
120 COVID-19 patients (89 critically ill, 15 severe, and 16 moderately severe) along with 80 healthy control were enrolled.The serum levels of HMGB1,IL1β, and α-klotho were determined by ELISA. The HMGB1 rs1045411 polymorphism was detected by RT- PCR.
Results:
The serum levels of HMGB1, IL1β, and α-klotho were significantly higher in critically ill COVID-19 patients compared to other groups. The HMGB1rs1045411 polymorphism revealed a significant decrease in the percentage of T/T genotypes in COVID-19 patients compared to controls. The (ROC) analysis showed moderate diagnostic potential for serum HMGB1, IL1β, and α-klotho.
Conclusion:
The serum HMGB1, IL1β, and α-klotho may be severity markers and promising therapeutic targets for COVID-19 patients.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
The JAK-STAT Signaling Pathway

